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Abstract
Aim: Cholinergic regulation is important in the control of
cardiovascular and endocrine responses. The mechanisms
behind cardiovascular responses induced by cholinergic acti-
vation are explored by studying hormonal systems, including
renin-angiotensin and vasopressin (VP).
Results: In chronically prepared fetal sheep, intravenous
infusion of the cholinergic agonist carbachol increased fetal
systolic, diastolic, and mean arterial pressure accompanied
with bradycardia at near-term. Although intravenous admin-
istration of carbachol had no effect on plasma VP concen-
trations, this agonist increased angiotensin I and angiotensin
II levels in fetal plasma. Fetal blood values, including sodi-
um, osmolality, nitric oxide, hemoglobin, and hematocrit
were unchanged by intravenous carbachol.
Conclusion: Cholinergic activation by carbachol controls
fetal blood pressure and heart rate in utero. An over-activated
fetal renin-angiotensin-system (RAS) is associated with
changes in vascular pressure following intravenous admin-
istration of carbachol, indicating that the cholinergic stimu-
lation-mediated hormonal mechanism in the fetus might play
a critical role in the regulation of cardiovascular homeostasis.
Keywords: Cholinergic activation; fetal RAS; osmoregula-
tion; vasopressin.
Introduction
Nicotine, a cholinergic agonist, is one of major chemicals
affecting fetuses exposed to smoking during pregnancy. Cho-
linergic mechanisms play an important role in the control of
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cardiovascular, body fluids, and endocrine systems in the
body w4, 6, 11, 21x. Numerous studies have demonstrated
that administration of the cholinergic agonist carbachol can
produce changes in blood pressure in adults w9, 19x. Recently,
it was shown that alteration of fetal development by envi-
ronmental insults may impact on postnatal health and
increased risks of diseases during adult life, including hyper-
tension and metabolic illness w9, 19x. Therefore, it is impor-
tant to study the functional development of the fetal
cardiovascular and hormonal systems in response to cholin-
ergic signals in utero.
Although the peripheral carbachol-mediated cardiovascu-
lar regulation in fetuses is still largely unknown, previous
studies has shown that central muscarinic modulation by
administration of pilocarpine could cause a very short period
of hypotension subsequently followed by a significant
increase in systolic, diastolic and pulse pressures in the ovine
fetus w20x. One recent report demonstrated that central injec-
tion of carbachol in the fetus can cause an increase of mean
arterial pressure w18x. In the present study, we determined the
influence of carbachol in the peripheral circulation on fetal
cardiovascular and hormonal responses in the fetus at near-
term.
Our study of hormonal responses induced by cholinergic
activation focused in the present study on the renin-angio-
tensin-system (RAS) and on vasopressin (VP). There are
functional relations between these hormones and cholinergic
activation, and both angiotensin and VP peptides contribute
to the control of cardiovascular systems w14, 17x. For exam-
ple, renin activity was significantly increased by cholinergic
mechanisms and RAS was shown to mediate carbachol pro-
duced pressor responses in adult animals w14x. However,
whether and to which extent that peripheral cholinergic stim-
ulation may affect expression of angiotensin I, angiotensin
II, and VP in the fetus is still unknown. Thus, the experi-
ments in the present study were designed to determine fetal
RAS and VP activity associated with cardiovascular
responses. Information gained might be important not only
to further understanding the fetal functional development,
but also to adding knowledge for disease development and




Time-dated pregnant ewes with fetuses (127"3 days of gestation
on the study day; term: 145 days) were used. Animals were housed
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Table 1 Fetal arterial values before and after intravenous infusion of vehicle or carbachol into the fetus.
Time after carbachol infusion
Baseline 5 min 30 min 90 min
Hct (%) (1) 28.01"1.15 28.05"1.65 25.67"2.62 27.17"1.83
(2) 27.33"0.33 26.67"0.88 27.33"0.33 26.00"1.15
Hb (g/dL) (1) 8.47"0.14 8.37"0.33 8.08"0.45 8.03"0.34
(2) 8.47"0.21 8.33"0.09 8.43"0.12 8.00"0.15
pH (1) 7.40"0.01 7.38"0.01 7.38"0.01 7.38"0.01
(2) 7.40"0.01 7.40"0.00 7.41"0.01 7.41"0.01
PCO2 (mm Hg) (1) 21.21"0.59 48.43"1.03 48.50"1.47 48.37"2.30
(2) 48.09"0.71 49.63"1.64 47.20"0.74 47.31"0.59
PO2 (mm Hg) (1) 21.21"0.59 20.70"0.83 20.81"0.87 21.43"0.75
(2) 21.82"1.66 21.26"1.01 22.97"1.96 21.87"0.91
Osmolality (mosmol/kg) (1) 301.00"13.58 306.60"5.40 301.80"4.37 300.25"12.63
(2) 300.33"1.20 304.33"4.91 302.00"1.53 305.33"1.45
Naq (meq/L) (1) 136.68"0.86 135.73"1.26 137.05"1.30 136.17"1.05
(2) 138.20"1.35 138.00"1.55 138.17"1.68 138.70"1.62
Kq (meq/L) (1) 3.97"0.23 3.93"0.24 3.60"0.24 3.95"0.13
(2) 4.08"0.80 3.86"0.59 3.94"0.74 3.76"0.52
Values are means"SEM. (1), iv infusion of carbachol (5 mg/kg); (2), iv infusion of vehicle (0.9% NaCl).
Hctshematocrit, Hbshemoglobin.
in individual study cages and in a light-controlled room (12:12-h
light-dark cycle) with food and water provided ad libitum. All sur-
gical and experimental procedures had been approved by the Insti-
tute’s Animal Care Committee.
Surgical preparation
Anesthesia was injected with ketamine hydrochloride (20 mg/kg
IM), and general anesthesia was maintained with 3% isoflurane and
1 L/min oxygen. The uterus was exposed by midline abdominal
incision, and a small hysterotomy was performed to provide access
to a fetal hind limb, as reported previously w24, 25x. Polyethylene
catheters (1.0 mm ID, 1.8 mm OD for the fetus) were placed in the
maternal and fetal femoral vein and artery and advanced to the
inferior vena cava and abdominal aorta, respectively. The fetus was
then returned into the uterus, and the hysterotomy was closed in
two layers. All catheters were externalized to the maternal flank and
placed in a cloth pouch. Immediately preoperatively and twice daily
during the initial two days of recovery, gentamicin (8 mg) and oxa-
cillin (30 mg) were administered intravenously to the fetus, and
gentamicin (70 mg) and oxacillin (1 g) were injected intravenously
into the ewe. Animals recovered for four days after surgery.
Experiments for blood values
Animals were divided into control (ns5) and experimental (ns5)
groups with computer-randomized selection. On the testing day,
sheep were allowed a period of 60–100 min to be acclimatized to
the testing room. When animal heart rates and arterial pressures
appeared to be stable, a 60-min baseline was followed by 15 min
of intravenous infusion and an additional 120 min period. Maternal
and fetal blood samples were collected at –30 and –5 min before
the intravenous infusion of carbachol, and at 5, 10, 30, 90 min after
infusion of carbachol (5 mg/kg) or vehicle (0.9% NaCl solution).
The dose was selected according to previous reports w16, 22x and
our preliminary testing. All fetal blood samples (3 ml/sample) were
replaced with equivalent volumes of heparinized maternal blood
withdrawn before the study, and all maternal blood samples were
replaced with equivalent volumes of isotonic saline. Blood samples
were withdrawn from the fetal and maternal arterial catheters for
measurements of blood PO2, PCO2, hemoglobin (Hb), pH, electro-
lyte concentrations by a Nova eleven-electrode analyzer (Nova Bio-
medical, Waltham, MA). Plasma osmolality was measured by using
freezing point depression on an advanced digimatic osmometer
(Model 3MO, Advanced Instruments, Needham Heights, MA).
Cardiovascular experiments
Beginning at time 0 (the beginning of intravenous infusions), car-
bachol (5 mg/kg, in 10 mL 0.9 NaCl; Sigma, St. Louis, MO) was
infused intravenously to the experiment fetus over 15 min. For the
control animals, the same volume of isotonic saline was infused
intravenously. Maternal and fetal blood pressures were monitored
during the testing period by means of a Power-Lab Physiological
Recorder (AD Instruments, Australia). Systolic, diastolic, and mean
arterial pressure, as well as heart rate was determined by computer
analysis of waveforms by utilizing the Chart 5 software (AD Instru-
ments, Australia).
Endocrine experiments
Maternal and fetal blood samples were collected into ice-cold tubes
containing lithium heparin during the baseline and study periods.
Blood samples for hormone assays were centrifuged immediately.
Samples were then stored at –208C before assays. All hormones
and biochemicals were measured by radioimmunoassay or biochem-
ical assay (Hua Ying Bio-tech Co, Beijing). The assay experiments
and data were handled in a blind manner.
Data analysis
Statistical analysis was preformed with repeated-measures ANOVA
(MANOVA). Comparisons before and after treatment were deter-
mined with Tukey post-hoc test. All data are expressed as
means"SEM, and statistical significance was set at P-0.05.
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Table 2 Material arterial values before and after intravenous infusion of vehicle or carbachol into the fetus.
Time after infusion carbachol
Baseline 5 min 30 min 90 min
pH (1) 7.46"0.01 7.44"0.02 7.47"0.01 7.45"0.01
(2) 7.47"0.01 7.47"0.01 7.47"0.01 7.48"0.03
PCO2 (mm Hg) (1) 24.33"0.98 24.97"1.23 25.93"1.27 24.87"1.30
(2) 24.01"1.51 26.61"0.21 23.91"1.15 25.72"1.25
PO2 (mm Hg) (1) 116.45"2.34 117.35"2.23 115.90"2.71 115.15"2.23
(2) 116.38"1.53 113.02"2.40 117.76"6.57 115.13"1.23
Hct (%) (1) 30.60"0.81 30.60"1.21 28.40"2.23 30.60"1.60
(2) 28.00"0.58 29.00"1.00 28.67"1.20 28.33"1.33
SO2 (%) (1) 98.46"0.23 98.34"0.36 97.42"0.75 98.12"0.41
(2) 98.53"0.32 98.05"0.45 98.73"0.15 98.47"0.26
Hb (g/dL) (1) 10.18"0.32 10.20"0.40 9.42"0.75 10.20"0.54
(2) 9.97"0.19 10.20"0.20 9.87"0.32 9.73"0.37
Naq (mmol/L) (1) 142.66"0.45 144.28"0.60 144.46"0.70 144.20"0.67
(2) 145.20"1.01 144.65"1.15 145.03"1.75 146.47"1.19
Kq (mmol/L) (1) 3.87"0.03 3.90"0.10 3.57"0.28 3.99"0.06
(2) 3.99"0.07 4.04"0.03 3.80"0.13 4.01"0.14
Glu (mmol/L) (1) 4.49"0.08 3.39"0.09 3.06"0.26 3.00"0.48
(2) 4.38"0.19 4.63"0.43 4.45"0.49 4.47"0.54
Osmolality (mosmol/kg) (1) 301.20"2.75 302.00"3.79 308.00"2.77 302.80"2.22
(2) 301.67"3.18 302.33"1.85 303.00"2.08 307.50"0.50
Values are means"SEM. (1), iv infusion of carbachol (5 mg/kg); (2), iv infusion of vehicle (0.9% NaCl).
Hctshematocrit, Hbshemoglobin, Glusglucose.
Table 3 Maternal blood pressure and heart rate before and after intravenous of carbachol into the fetus.
Time after carbachol infusion
Baseline 5 min 15 min 30 min 90 min
SP (mm Hg) (1) 114.73"3.69 116.79"4.23 115.49"4.29 115.52"4.88 118.79"4.79
(2) 115.15"2.58 116.23"1.56 116.25"2.35 115.68"4.33 116.26"4.72
DP (mm Hg) (1) 82.75"3.10 83.21"2.91 82.09"4.07 84.31"4.27 82.96"3.25
(2) 82.76"3.25 83.20"2.81 82.50"3.58 82.41"4.03 82.33"3.36
MAP (mm Hg) (1) 95.92"2.62 96.46"2.77 95.71"3.74 98.17"3.96 97.52"3.08
(2) 95.08"2.36 95.47"3.12 95.26"3.15 97.02"3.36 96.25"2.63
HR (bpm) (1) 121.75"7.73 125.11"8.77 123.79"7.84 124.43"7.43 125.78"7.73
(2) 120.39"6.58 125.08"7.33 125.79"6.86 124.53"7.53 126.13"8.06
Values are means"SEM. (1), iv infusion of carbachol (5 mg/kg); (2), iv infusion of vehicle (0.9% NaCl).
SPssystolic pressure, DPsdiastolic pressure, MAPsmean arterial pressure.
Results
Blood values
There was no significant difference in fetal arterial blood pH,
PO2, PCO2, Hb, and hematocrit (Hct) before or after intra-
venous infusion of carbachol (Table 1). For both the control
and the experiment fetuses, intravenous infusion of carbachol
or vehicle had no effect on plasma osmolality levels
(P)0.05) in the fetuses. Fetal blood Kq and Naq concen-
trations were not changed between the control and the exper-
imental groups. All arterial values were within normal ranges
and did not vary significantly between the control and exper-
imental groups (all P)0.05). In the ewes, intravenous infu-
sion of carbachol or vehicle into the fetuses had no effect
on plasma osmolality (P)0.05). Maternal blood Naq and
Kq concentrations, blood pH, PO2, and PCO2 were not sig-
nificantly changed between the control and experimental
groups (all P)0.05, Table 2).
Cardiovascular responses
There was no significant difference in maternal systolic, dia-
stolic, mean arterial pressure, and heart rate between the
control and experimental groups (P)0.05, Table 3). Fetal
systolic, diastolic, and mean arterial pressure were first
decreased for a short time, and then increased following
intravenous administration of carbachol (Figure 1). The
increased fetal blood pressure returned to baseline within
30 min after infusion. Fetal heart rate was significantly
decreased (P-0.01) after administration of carbachol (Figure
2).
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Figure 1 Effect of intravenous injection of vehicle or carbachol
on the preterm fetal systolic pressure (SP, mm Hg), diastolic pres-
sure (DP, mm Hg), and mean arterial pressure (MAP, mm Hg).
0 min, time of intravenous injection. *P-0.05 (statistical signifi-
cant) compared with the baseline level (ns5/each group).
Figure 2 Effect of intravenous injection of vehicle or carbachol
on the preterm fetal heart rate (in beats/min). 0 min, time of intra-
venous injection. *P-0.05 (statistical significant) compared with
the baseline level (ns5/each group).
Fetal plasma hormones
Although there was no difference in fetal plasma VP con-
centrations before and after intravenous infusion of carbachol
into the fetus and between the control and experimental
groups (Table 4), fetal plasma Ang I and Ang II levels were
significantly increased (from 1.75"0.23 and 108.61"3.15
to 2.72"0.31 ng/mL and 127.98"7.20 pg/mL, respectively)
within 5 min after intravenous carbachol (Figure 3).
Discussion
Although cholinergic systems are important in the control of
cardiovascular homeostasis w1–3, 5x, limited data existed on
the functional development of cholinergic mechanisms in
regulation of fetal vascular and endocrine systems. In the
present study, we found that cholinergic activation by intra-
venous carbachol affected fetal blood pressure in association
with an increase of fetal RAS activity.
In the chronically prepared ovine fetuses, intravenous
administration of the cholinergic agonist induced changes of
fetal blood pressure at near-term in the present study. The
involvement of the autonomic nervous system in the control
of cardiovascular responses following administration of cho-
linergic agents has been investigated in adult animals w15,
23x. Carbachol could increase sympathetic nervous system
activity, which increases blood pressure. The increased blood
pressure activates a baroreflex-mediated bradycardia by
increasing vagal tone w12x. We observed a short period of
decrease of fetal blood pressure accompanied by bradycardia
immediately after intravenous infusion of carbachol in the
present study. Although a previous study found fetal cardio-
vascular responses caused by the muscarinic agonist pilo-
carpine w20x, the present study was the first to demonstrate
that carbachol could induce a short decrease of fetal blood
pressure (this could be due to immediate decrease of fetal
heart rate), followed by an increase of fetal systolic, diastolic,
and mean arterial pressure at near-term pregnancies. A ques-
tion raised immediately was what were the mechanisms for
the cholinergic stimulation induced fetal blood pressure
responses?
Notably, the main trend in the change of fetal blood pres-
sure by carbachol in the present study was an increase of
arterial pressure. Many factors may contribute to choliner-
gic stimulation-induced cardiovascular responses w8, 13x.
Besides autonomic control mechanisms, endocrine contri-
bution also has an important role. For example, RAS medi-
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Table 4 Fetal plasma VP values before and after intravenous infusion of carbachol into the fetus.
Time after carbachol infusion
Baseline 5 min 30 min 90 min
AVP (pg/mL) (1) 10.91"0.89 11.10"0.89 9.91"2.20 10.71"0.65
(2) 9.65"0.55 9.35"0.65 9.36"1.00 9.49"0.37
Values are means"SEM. (1), iv infusion of carbachol (5 mg/kg); (2), iv infusion of vehicle (0.9% NaCl).
VPsvasopressin.
Figure 3 Effect of intravenous (iv) infusion of vehicle or car-
bachol on fetal plasma angiotensin I, angiotensin II levels. *P-0.05
(statistical significant) compared with baseline level (ns5/each
group).
ated carbachol produced pressor responses w24x. Renin
release could be regulated by cholinergic mechanisms w14x.
In the present study, angiotensin I and II concentrations were
significantly increased in the fetus following infusion of
intravenous carbachol suggesting that cholinergic signal-
increased higher blood pressure may partially be mediated
by angiotensin mechanisms. Further pharmacological studies
using angiotensin II antagonists might yield additional infor-
mation as to whether direct or indirect mechanisms increased
RAS activity in the circulation. To the best of our knowledge,
this study was the first to provide evidence in the fetus that
cholinergic stimulation can activate RAS that may contribute
to carbachol-induced pressor responses also. It also demon-
strates a link between cholinergic activation and angioten-
sinergic systems that developed and became functional in
utero near-term.
In addition to angiotensin II, the cholinergic agonist car-
bachol is also well known in body fluid balance w10, 13x.
Injection of carbachol in conscious animals can increase
water intake and stimulate release of hypothalamic VP w7x,
resulting in changes of vascular volume and/or vessel tone.
Previous studies have shown that an increase of VP levels
in the circulation is a potent stimulus for pressor responses
w19x. However, in the present study, we did not observe any
change of plasma VP concentrations in the fetus treated with
carbachol. Therefore, we can exclude the possibility of VP
mechanisms that may be involved in carbachol-increased
fetal blood pressure.
As mentioned above, administration of carbachol into ani-
mals can induce drinking w10, 13x and may influence osmo-
regulation, which might cause changes of body fluids and
vascular volume. In the present study, we monitored blood
electrolytes levels and plasma osmolality in both maternal
and fetal sheep during the testing periods. There was no
change of blood sodium concentrations and plasma osmo-
lality in the mother and fetus following administration of
carbachol. In addition, fetal Hct levels were unchanged by
intravenous infusion of carbachol. Together, the data did not
support the possibility that carbachol may cause change of
fetal body fluids in contribution to the increased blood
pressure.
Conclusion
The finding showed that cholinergic activation by peripheral
carbachol was involved in the control of fetal blood pressure
and heart rate. Interestingly, in investigation of hormonal and
chemical mechanisms that contribute to cholinergic signal-
stimulated cardiovascular responses, we found an over-acti-
vated fetal RAS associated with changes of vascular pressure
following intravenous administration of carbachol. This pro-
vides new evidence that both cholinergic and angiotensin-
ergic systems have functionally developed in utero at
near-term, and offers new insight that the cholinergic stim-
ulation-mediated hormonal mechanism may also play a role
in the regulation of fetal cardiovascular homeostasis. Con-
sidering that many environmental factors such as smoking
during pregnancy may affect cholinergic activation in utero,
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the findings in the present study are important to both pre-
natal and postnatal health.
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